- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02235870
Obalon Balloon System Pivotal IDE (SMART) Trial (SMART)
The Six-Month Adjunctive Weight Reduction Therapy (SMART) Trial
This pivotal trial of the Obalon Balloon System is intended to generate safety and effectiveness data required to support a future marketing application. The trial has been designed to evaluate a 6-month use of the Obalon Balloon System as an adjunct to a nutrition and lifestyle behavior modification program.
Weight loss will be evaluated after the 6-month course to determine if a specific predefined superiority margin can be achieved in the device group compared to a sham-control group.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States
- HonorHealth Research Institute
-
-
California
-
Anaheim, California, United States
- Anaheim Clinical Trials
-
Coronado, California, United States
- Southern California Research Center
-
-
Illinois
-
Hinsdale, Illinois, United States
- Bariatric Institute of Greater Chicago
-
-
Maryland
-
Towson, Maryland, United States
- Endoscopic Microsurgery Associates
-
-
Missouri
-
Kansas City, Missouri, United States
- Saint Luke's Hospital of Kansas City
-
Saint Louis, Missouri, United States
- Washington University Hospital in St. Louis
-
-
New York
-
Stony Brook, New York, United States
- Stony Brook Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States
- West Penn Hospital
-
-
Tennessee
-
Chattanooga, Tennessee, United States
- Chattanooga Bariatrics
-
Memphis, Tennessee, United States
- MidSouth Bariatrics
-
Nashville, Tennessee, United States
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States
- Houston Methodist Research Institute
-
-
Utah
-
Salt Lake City, Utah, United States
- University of Utah Hospital
-
-
Washington
-
Seattle, Washington, United States
- Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between the ages of 22-64 years
- Current BMI of 30.0 - 40 kg/m2
- Previously attempted to lose weight unsuccessfully using a medically supervised or non-medically supervised diet
- Willing to attend all protocol-specified follow-up visits plus any additional follow-up visits as required throughout the entire study period
- Willing to avoid non-commercial air travel and scuba diving during the entire study period
- Willing to avoid medications or other substances known to effect weight changes during the study
- Willing to avoid Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or other medications known to be gastric irritants during the study
- Willing to use contraception and avoid pregnancy during the study if the subject is female with child bearing potential
- Willing to provide written informed consent
Exclusion Criteria:
- Significant weight loss in the past 12 months
- Use of medications or other substances known to induce weight gain or weight loss
- Participation in any clinical study at the start of this trial or in the last year
- Known history of endocrine disorders affecting weight
- Currently receiving chronic steroid or immunosuppressive therapy or has previously been diagnosed with HIV
- Subjects diagnosed with bulimia, binge eating, compulsive overeating, high liquid calorie intake habits or similar eating related psychological disorders
- Intent to undergo gastric surgery or gastric banding during the study period or within the 6 month period after completion of this study
- Prior use of any weight loss medical device
- Known history of structural or functional disorders of the esophagus
- Known history of structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal reflux symptoms
- Known history of structural or functional disorders of the stomach
- Known history of a structural or functional disorder of the stomach, including any symptoms of chronic upper abdominal pain, chronic nausea, chronic vomiting, chronic dyspepsia or symptoms suggestive of gastroparesis, including post-prandial fullness or pain, post-prandial nausea or vomiting or early satiety
- Known history of duodenal ulcer, intestinal diverticula (diverticulitis), intestinal varices, intestinal stricture/stenosis, small bowel obstruction, or any other obstructive disorder of the gastrointestinal (GI) tract
- Currently have ongoing symptoms suggestive of intermittent small bowel obstruction, such as recurrent bouts of post-prandial abdominal pain, nausea or vomiting
- Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease
- Known history of GI surgeries that may have resulted in anatomical GI tract abnormalities
- Type 1 diabetes
- Type 2 diabetes requiring insulin or other hypoglycemic oral agents.
- Experienced a myocardial infarction, has a known history of angina, a known history of congestive heart failure, or is currently being medically treated for any other cardiac condition
- Poorly controlled hypertension, (≥ 160 mmHg Systolic and ≥ 100mmHg Diastolic).
- End stage renal disease or requiring hemodialysis within the past 6 months
- Unwilling or unable to avoid Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin, Diclofenac, Ibuprofen, Naproxen, or other medications known to be gastric irritants beginning two weeks prior to enrollment and throughout the entire study period
- Subjects taking medications on specified hourly intervals that may be affected by changes to gastric emptying
- Subjects requiring the use of anti-platelet drugs or other agents affecting the normal clotting of blood
- Untreated or unstable alcohol or illicit drug addiction
- Known history of allergies to any component of the device materials
- Currently pregnant or breastfeeding or intention of becoming pregnant during the study
- Life expectancy less than 1 year or severe renal, hepatic, pulmonary or other medical condition, in the opinion of the investigator
- Subject is employed by the investigator, or is a close relative of the investigator, or the investigator's staff
- Subject is a close relative of another subject already enrolled in the study.
- Any other condition that, in the opinion of the investigator, would interfere with subject participation, may confound the study results, or interfere with compliance with the study (e.g., psychosocial issues).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment Group
In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program.
Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
|
Intragastric Balloon System to aid in portion control.
Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
|
Sham Comparator: Control Group
Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program.
Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
|
Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
Sham Intragastric Balloon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Least-Square Mean Difference in % Total Body Loss (TBL) Between the Obalon Treatment and Sham Control Groups
Time Frame: 24 Weeks
|
Statistical test to determine if the least-square mean difference between the Obalon Treatment and Sham Control groups is greater than the 2.1% TBL superiority margin
|
24 Weeks
|
Percentage of Subjects in the Obalon Treatment Group With at Least 5% Total Body Loss (TBL)
Time Frame: 6 months
|
Statistical test to determine if the percentage of subjects in the Obalon Treatment and Sham Control with at least 5% Total Body Loss (TBL) is greater than 35%
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With at Least 5% Total Body Loss: Obalon - Sham Group
Time Frame: 6 Months
|
Difference in percentage of subjects between the Obalon Treatment and Sham Control groups with at least 5% Total Body Loss (TBL)
|
6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Amy VandenBerg, Obalon Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTL-1100-0013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Obalon Intragastric Balloons
-
University Hospital OstravaActive, not recruiting
-
Obalon Therapeutics, Inc.CompletedObesity | Weight ControlBelgium, France
-
University Hospital BirminghamBoston Scientific CorporationUnknownStenosis | Native Arteriovenous FistulaUnited Kingdom
-
Surgical Specialists of LouisianaObalon Therapeutics, Inc.CompletedObesity
-
Obalon Therapeutics, Inc.Unknown
-
Obalon Therapeutics, Inc.Recruiting
-
Obalon Therapeutics, Inc.Completed
-
Bambino Gesù Hospital and Research InstituteCompletedSevere Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-) | Altered Liver Function Tests | Glycemic IntoleranceItaly
-
Prof Dr Jan TackCompletedFunctional Disorders of StomachBelgium
-
Chinese University of Hong KongUnknown